Tamoxifen
Springer Basel (Verlag)
978-3-0348-0663-3 (ISBN)
Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.
This monograph, written by V. Craig Jordan - known as the "father of tamoxifen" - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a "failed morning after contraceptive" to become the "gold standard" for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen's pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens.- Tamoxifen Goes Forward Alone.- Metabolites of Tamoxifen as the Basis of Drug Development.- Adjuvant Therapy - The Breakthrough.- The Wisconsin Story in the 1980's: Discovery of Target Site Specific Estrogen Action.- Carcinogenesis and Tamoxifen.- Chemoprevention: Cinderella waiting for the ball.- Tamoxifen and Raloxifene head to head: The STAR TRIAL.- Acquired resistance to Tamoxifen: back to the beginning.- The legacy of Tamoxifen.- Appendix: Four decades of discovery in breast cancer research and treatment - an interview with V. Craig Jordan by Marc Poirot.- Selected Awards that Recognize the Contribution of Tamoxifen and Raloxifene to Medicine.
From the book reviews:
"This is a book that had to be written. ... This book should be available in every oncology department. The story will interest clinicians and laboratory scientists alike. It has both historical value and value as a guide that will illuminate the path to successful involvement in cancer research for younger cancer researchers." (R. M. Lowenthal, Inflammopharmacology, Vol. 22 (3), June, 2014)
"This is a very well-written, readable book for anyone who has an interest in the prevention and treatment of breast cancer, ranging from those involved in drug discovery to those who are treating and taking care of patients with breast cancer. Likewise, anyone who has a loved one who has, or is at high risk for, breast cancer will find this an excellent read. ... It is a well-done and interesting read." (Thomas L. Pazdernik, Doody's Book Reviews, November, 2013)| Erscheint lt. Verlag | 6.8.2013 |
|---|---|
| Reihe/Serie | Milestones in Drug Therapy |
| Zusatzinfo | XXII, 199 p. 54 illus. |
| Verlagsort | Basel |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Gewicht | 474 g |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Medizin / Pharmazie ► Studium | |
| Schlagworte | Anti-estrogens • Apoptosis • Breast Cancer • Estrogen Receptor • SERMS |
| ISBN-10 | 3-0348-0663-9 / 3034806639 |
| ISBN-13 | 978-3-0348-0663-3 / 9783034806633 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
